←
Brian Finrow576 posts
Brian Finrow avatar

Brian Finrow

@Finrow

Founder/CEO at Lumen Bio. I'm a quasi-outsider to the biopharma industry, interested in the economics of drug development.

◷ Joined August 2009▧ 37 Photos and videos
Nature Unedited avatar
⟳ Brian Finrow retweeted
Nature Unedited@NatureUnedited·Nov 15

First-ever footage of a barreleye fish, with its eyes visible inside its transparent head

1:32
1Day Sooner avatar
⟳ Brian Finrow retweeted
1Day Sooner@1daysooner·Nov 5

Clinical trials in the US are slow, costly, and often out of reach for patients who might benefit from participation. 1Day Sooner and 18 organizations, 13 of them rare disease groups, are backing the bipartisan Faster Clinical Trials Act from @RepAuchincloss and @RepMGriffith.

Infinita is proudly declaring its support for the "Faster Clinical Trials Act", a bipartisan bill introduced by Reps. @JakeAuch (D-MA) and @RepMGriffith (R-VA). Clinical trial reform at the federal level has suffered from a lack of ambition. This is the first bill that I've seen that is not lacking ambition whatsoever. "The bill also sets targets to reduce the cost per patient for the clinical trials conducted by these networks by 30 to 50 percent and speed participant enrollment in those trials by 30 percent." The mechanisms how to reduce costs are a distillation best policy research that I've seen over the years, incl. by @IFP, @RuxandraTeslo, @sytses & many more The things I am most excited about: - Bringing evidence generation closer into the clinic; proving real-world effectiveness has been an afterthought in FDA approvals, leading to lack of safety & efficacy - Streamlined trial site networks that can be accessed via a "multi-site, single-IRB", overcoming the IRB fragmentation that is a major source of delay in early research - Governance sandboxes - critically, the bill does not make the mistake of trying to fix everything at once. Its mandate is to support sandboxes, innovative trial models With this, the US has a real shot at retaining its competitive advantage in biotech, and could do right by millions of patients to access trials in the US instead of abroad.

Post attachment
Derek Thompson avatar
⟳ Brian Finrow retweeted
Derek Thompson@DKThomp·Nov 5

There's a lot to focus on right now, but "The richest man to ever live just spent $200 million to support the Republican Senate candidate in Texas, and his man lost by double-digits in a statewide wipeout" is a completely insane sentence. Put another way, the most expensive US Senate race before 2020 was $200 million. *One guy* spent that amount in Texas, and it doesn't seem to have made any difference. It might have hurt in a kind of Streisand effect way, in that the spending level was seen as obscene to people sympathetic to the argument that billionaires shouldn't "buy" elections. The implications here seem pretty interesting! Especially re the limits of billionaire political power and/or the diminishing returns of money in politics.

Erik Brynjolfsson avatar
⟳ Brian Finrow retweeted
Erik Brynjolfsson@erikbryn·Nov 5

Evidence is growing that we’re turning the corner on productivity. US productivity grew at a 3.6% annual rate this past quarter. That’s more than double the 1.5% average from 2007-2019. The new numbers put me further ahead for my bet with Bob Gordon about productivity growth in the 2020s. 💪 Here’s how far the US is now ahead of the CBO estimate at the start of the decade (before they knew about the pandemic or LLMs) courtesy of @jasonfurman’s Econvitals.

Post attachment
Ben Southwood avatar
⟳ Brian Finrow retweeted
Ben Southwood@bswud·Nov 3

The best cultural criticism is impossible to unsee: the comparisons are so obviously true that once explained, they set in the back of one's minds forever. It almost feels like they have always been there, that they are obvious. So it is with Sitte, and with this excellent piece about his guide to building wonderful cities.

How can we make lovable cities? If you had asked a European architect this question in 1900, they would probably have referred you to a slender, lively book by the Austrian writer Camillo Sitte, translated as ‘The Art of Building Cities’. Published in 1889, ‘The Art of Building Cities’ swiftly came to be revered around the world. worksinprogress.co/issue/the… Sitte was repudiated by the modernists and fell into obscurity, but his ideas are beginning to be revived. My cousin @PMArslanagic and I have distilled nineteenth century's finest work on urbanism into five principles: - Create enclosed spaces - Keep squares small - Symmetry is overrated - Move monuments to the edges of spaces - Nestle monuments in vernacular fabric

Brian Finrow avatar
Brian Finrow@Finrow·Nov 2

Making drugs in Chinese hamster ovary cells (!) surely looked very weird med-chem pharma folks in the 80s, and thank goodness the visionaries at Amgen and Genentech went for it anyway!

Brian Finrow avatar
Brian Finrow@Finrow·Nov 2

Now, it might be that AI-designed drugs *also* lackluster, but since nearly all pharmas and VCs *hate* investing in novel modalities (@rtnarch excepted) it’s hardly a fair test. AI-designed or not, new drugs can’t be developed without funding. If not enough investors jump into the deeply novel (and weird-looking) end of the pool, we won’t get to find out.

Brian Finrow avatar
Brian Finrow@Finrow·Nov 2

Thoughtful piece from @LifeSciVC (link in replies) But Bruce’s causal story seems backwards to me: most *observable* AI-designed drug molecules are me-too’s precisely because that’s what VCs and big pharma prefer to fund! It’s survivorship bias: the hypothetical full data set is quietly censored at the funding stage by investors, most of whom are skittish about novel target risk.

Post attachment
Ali Mortazavi avatar
⟳ Brian Finrow retweeted
Ali Mortazavi@AAMortazavi·Oct 27

Biotech companies will materially change their form and shape. Old structures are gone. But AI is a massive injection of new capital into drug dev and biotech. Start a biotech company - just a very different one from before. $XBI

Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

Ashwin Varma, MD avatar
⟳ Brian Finrow retweeted
Ashwin Varma, MD@varma_ashwin97·Oct 24

It just comes down to structural factors: wages, the number of people, the organization of the healthcare system, and SOC. Wages are low, despite essentially 0 difference in skill, hours are longer, SOC is bad+people are many → speeding enrollment.